|
Circulating tumor DNA profiling of lung cancer patients treated with EGFR inhibitors. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Inivata |
Travel, Accommodations, Expenses - Inivata |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Inivata |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Roche; Roche |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis |
Research Funding - AstraZeneca (Inst); Roche (Inst) |
|
|
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst) |
Expert Testimony - Inivata |
Travel, Accommodations, Expenses - AstraZeneca; Roche |